Leap Therapeutics Inc

Leap Therapeutics insider RSU settlements signal long‑term confidence in its hybrid oncology‑and‑blockchain model, boosting investor sentiment and strategic positioning.

Insider buys by Leap Therapeutics executives signal confidence in the company’s Phase‑2 drug pipeline and digital‑asset strategy, suggesting undervalued upside potential for long‑term investors.

Leap Therapeutics insiders convert RSUs to shares, boosting float & signaling confidence amid a 39% weekly rally—an insider‑backed signal for investors to watch its dual‑track clinical and digital‑asset strategy.

Leap Therapeutics insider buying signals bullish confidence as the oncology and privacy‑tech firm advances its Phase‑2 sirexatamab program, positioning for future growth.